Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Related Articles
Anumana, Pfizer collaborate on AI-based detection of cardiovascular disease
NS Medical Devices: The research agreement with Pfizer will aid Anumana to develop an AI-enabled ECG algorithm to help detect patients who may be at risk of cardiac amyloidosis{post_date: F d, Y}
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG Data
Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG DataCAMBRIDGE, Mass, June 27, 2024 Anumana, a leading AI-driven health technology company…{post_date: F d, Y}
Anumana Names Dr. Simos Kedikoglou President & COO
AI Tech 365: Anumana, a leading AI-driven health technology company, announced the appointment of Dr. Simos Kedikoglou as President and Chief Operating Officer (COO), effective immediately.{post_date: F d, Y}
Midwest providers eye new financial opportunities
Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster…{post_date: F d, Y}